The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 06, 2018

Filed:

Apr. 10, 2015
Applicants:

National University Corporation University of Toyama, Toyama, JP;

Kracie Pharma, Ltd., Tokyo, JP;

National Cancer Center, Tokyo, JP;

Tokyo University of Science Foundation, Tokyo, JP;

Inventors:

Hiroyasu Esumi, Tokyo, JP;

Masafumi Ikeda, Chiba, JP;

Katsuya Tsuchihara, Chiba, JP;

Shigeki Chiba, Toyama, JP;

Satoshi Yomoda, Toyama, JP;

Takanori Kawashima, Toyama, JP;

Toshiki Okubo, Toyama, JP;

Yasuhiro Tezuka, Toyama, JP;

Kenta Murata, Toyama, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/34 (2006.01); A61K 36/00 (2006.01); A61K 47/22 (2006.01); A61K 36/28 (2006.01); A61K 31/7068 (2006.01); A61K 45/06 (2006.01); A61K 47/46 (2006.01); A61K 39/395 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/22 (2013.01); A61K 31/7068 (2013.01); A61K 36/28 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/46 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract

The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.


Find Patent Forward Citations

Loading…